A phase I dose-escalation study of CST-101 in patients with Advanced Renal Cell Carcinoma and Melanoma susceptible to immunotherapies.

Trial Profile

A phase I dose-escalation study of CST-101 in patients with Advanced Renal Cell Carcinoma and Melanoma susceptible to immunotherapies.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2016

At a glance

  • Drugs CST 101 (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Mar 2016 New trial record
    • 07 Feb 2016 Clinical data from the first 12 patients of the U.S. trial at Rush University Medical Center in Chicago has been announced recently, as per the University of Pittsburgh Medical Center (UPMC) media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top